Midazolam oral solution - Advicenne

Drug Profile

Midazolam oral solution - Advicenne

Latest Information Update: 30 Sep 2015

Price : $50

At a glance

  • Originator Advicenne
  • Class Benzodiazepines; Hypnosedatives; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Sedation

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 30 Sep 2015 Preregistration for Sedation (PO) (before 30 September 2015)
  • 01 Sep 2015 Phase-II clinical trials in Sedation (In children, In adolescents) in France (PO) (3144645; before September 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top